Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 11/20 | 0.42 |
| ▸ | PLK1 | P53350 | 2/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 4/20 | 0.35 |
| ▸ | SRC | P12931 | 4/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213397 | 0.91 | WEE1 (0.49) | WEE1PLK1AXLBTK | |
| SCHEMBL215264 | 0.91 | WEE1 (0.47) | WEE1PLK1AXLBTK | |
| SCHEMBL8511197 | 0.90 | WEE1 (0.46) | WEE1PLK1AXLBTK | |
| SCHEMBL9609440 | 0.88 | WEE1 (0.43) | WEE1PLK1AXLSRCBTK | |
| SCHEMBL215998 | 0.85 | WEE1 (0.55) | WEE1PLK1LCKSRCKDR | |
| SCHEMBL8509718 | 0.83 | WEE1 (0.49) | WEE1PLK1BTK | |
| SCHEMBL8511335 | 0.82 | WEE1 (0.52) | WEE1PLK1LCKSRCKDR | |
| SCHEMBL8513897 | 0.82 | CAMK2D (0.44) | WEE1AXLLCKSRCKDR | |
| SCHEMBL8514074 | 0.81 | WEE1 (0.43) | WEE1PLK1LCKSRCKDR | |
| SCHEMBL8513938 | 0.80 | WEE1 (0.48) | WEE1LCKSRCKDRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | WEE1 1/4885PLK1 636/4885MAP3K14 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.